Trophoblast cell surface antigen 2 (Trop2) is overexpressed in a range of solid tumors and
participants in multiple oncogenic signaling pathways, making it an attractive therapeutic …

Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom
systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 …

Protein tyrosine kinase 7 (PTK7), a catalytically defective receptor protein tyrosine kinase, is
frequently upregulated in various cancers, including triple-negative breast cancer (TNBC) …

Antibody–drug conjugates (ADCs) represent one of the most promising and rapidly
emerging anti-cancer therapies because they combine the cytotoxic effect of the conjugate …

Background: The persistence of chemotherapy-resistant and dormant cancer cells remains a
critical challenge in the treatment of lung cancer. Objectives: This review focuses on non …

The present review provides a detailed and comprehensive discussion on antibody–drug
conjugates (ADCs) as an evolving new modality in the current therapeutic landscape of …

Non-small-cell lung cancer (NSCLC) is a highly heterogeneous disease that is frequently
associated with a host of known oncogenic alterations. Advances in molecular diagnostics …

Recent advancements in cancer treatment have explored a variety of approaches to address
the needs of patients. Recently, immunotherapy has evolved as an efficacious treatment for …

Telisotuzumab is a monoclonal antibody and a novel anti-cancer drug that specifically binds
to the hepatocyte growth factor receptor (HGFR). In this study, we utilized atomic force …

During the last decades, a novel class of therapeutic agents has emerged in the target
treatment of hematological malignancies and solid tumors. Antibody-drug conjugates …